Primary Site >> Colorectal Cancer
Gene >> MAP2K7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Modulation of hepatocyte growth factor-induced scattering of HT29 colon carcinoma cells. Involvement of the MAPK pathway. PMID: 9512500 Ref: Oncogenic ras induces gastrin gene expression in colon cancer. PMID: 9797369 |
Ref: Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. PMID: 10086335 Ref: Mitogen-activated protein kinase activation regulates intestinal epithelial differentiation. PMID: 10220499 Ref: Glycine-extended gastrin exerts growth-promoting effects on human colon cancer cells. PMID: 10404512 Ref: Differential regulation of MAP kinase cascade in human colorectal tumorigenesis. PMID: 10584870 |
Ref: Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. PMID: 10910078 Ref: [Deregulation of intracellular signal pathways in colorectal carcinoma]. PMID: 10929640 |
Ref: Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. PMID: 11313939 Ref: MEK (MAPKK) inhibitors. Part 2: structure-activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines. PMID: 11378365 Ref: Alterations of MAPK activities associated with intestinal cell differentiation. PMID: 11394874 Ref: The protrusive phase and full development of integrin-dependent adhesions in colon epithelial cells require FAK- and ERK-mediated actin spike formation: deregulation in cancer cells. PMID: 11494115 Ref: Upregulation of non-mutated H-ras and its upstream and downstream signaling proteins in colorectal cancer. PMID: 11605075 |
Ref: The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. PMID: 11992399 Ref: Phorbol 12-myristate 13-acetate up-regulates the transcription of MUC2 intestinal mucin via Ras, ERK, and NF-kappa B. PMID: 12077118 Ref: Therapeutics targeting signal transduction for patients with colorectal carcinoma. PMID: 12421735 |
Ref: Oncogenic ras induces gastrin/CCKB receptor gene expression in human colon cancer cell lines LoVo and Colo320HSR. PMID: 12761477 Ref: MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-activated receptor 2. PMID: 14511767 Ref: Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. PMID: 14556662 |
Ref: Pressure activates colon cancer cell adhesion by inside-out focal adhesion complex and actin cytoskeletal signaling. PMID: 14699482 Ref: Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-kappaB-dependent pathway. PMID: 14981539 Ref: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. PMID: 14991899 Ref: Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)/pp32 in response to the antiproliferative lectin, jacalin. PMID: 15247276 Ref: Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status. PMID: 15325273 Ref: Luteolin sensitizes tumor necrosis factor-alpha-induced apoptosis in human tumor cells. PMID: 15334063 Ref: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. PMID: 15483017 Ref: In vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human. PMID: 15497695 Ref: Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. PMID: 15548677 |
Ref: Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. PMID: 15494427 Ref: Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells. PMID: 15513932 Ref: Quinoxaline 1,4-dioxides induce G2/M cell cycle arrest and apoptosis in human colon cancer cells. PMID: 15538569 Ref: Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. PMID: 15605394 Ref: Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2-mediated proliferation of colon cancer cell. PMID: 15655297 Ref: The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. PMID: 15655409 Ref: Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. PMID: 15657353 Ref: Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. PMID: 15704157 Ref: BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. PMID: 15729718 Ref: IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. PMID: 15749028 Ref: Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. PMID: 15757891 Ref: Butyrate-induced differentiation of colon cancer cells is PKC and JNK dependent. PMID: 15810631 Ref: Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyri din-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxami PMID: 15901852 Ref: Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells. PMID: 16024641 Ref: Position of STAT-1 alpha in cycloheximide-dependent apoptosis triggered by TNF-alpha in human colorectal COLO 205 cancer cell line; role of polyphenolic compounds. PMID: 16077199 Ref: Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. PMID: 16093613 |
Ref: Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. PMID: 16278684 Ref: The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. PMID: 16288223 Ref: APC inhibits ERK pathway activation and cellular proliferation induced by RAS. PMID: 16478791 Ref: Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis. PMID: 16575407 Ref: Proline oxidase activates both intrinsic and extrinsic pathways for apoptosis: the role of ROS/superoxides, NFAT and MEK/ERK signaling. PMID: 16619034 Ref: Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells. PMID: 16631161 Ref: Octahedral Pt(IV) complex K101 induces apoptosis via ERK1/2 activation and the p53 pathway in human colon cancer cells. PMID: 16702812 Ref: [Role of calcium signal in apoptosis and protective mechanism of colon cancer cell line SW480 in response to 5-aminolevulinic acid-photodynamic therapy]. PMID: 16764761 Ref: Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. PMID: 16959882 Ref: Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. PMID: 17112382 Ref: Different modulation of TRAIL-induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells. PMID: 17113582 Ref: BRAF mutations in papillary thyroid carcinoma. PMID: 17201587 |
Ref: The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. PMID: 17374366 Ref: XAF1 mediates apoptosis through an extracellular signal-regulated kinase pathway in colon cancer. PMID: 17385215 Ref: Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. PMID: 17393356 Ref: Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways. PMID: 17531111 Ref: Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells--phosphorylated RXR alpha is a critical target for colon cancer management. PMID: 17604322 Ref: Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. PMID: 17620438 Ref: [Effects of extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activation on proliferation and cell cycle associated genes in human colon cancer cells]. PMID: 17650425 Ref: Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. PMID: 17699719 Ref: Keratinocyte growth factor-transfection-stimulated adhesion of colorectal cancer cells to extracellular matrices. PMID: 17706640 Ref: Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. PMID: 17909036 Ref: Alkoxymethylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor. PMID: 17952880 Ref: Therapeutic strategies for targeting BRAF in human cancer. PMID: 18473997 |
Ref: Kruppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis. PMID: 18054006 Ref: Regulation of MDMX expression by mitogenic signaling. PMID: 18172009 Ref: Response of normal and colon cancer epithelial cells to TNF-family apoptotic inducers. PMID: 18202809 Ref: A novel endogenous human CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest via p27 stabilization. PMID: 18305109 Ref: Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. PMID: 18372904 Ref: Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. PMID: 18375747 Ref: ANTI-ADHESION evolves to a promising therapeutic concept in oncology. PMID: 18393855 Ref: Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin. PMID: 18436711 Ref: Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. PMID: 18454176 Ref: Alpha2beta1 integrin regulates lineage commitment in multipotent human colorectal cancer cells. PMID: 18664572 Ref: Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. PMID: 18806830 Ref: PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells. PMID: 18854173 |
Ref: Docosahexaenoic acid induces apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 MAPK pathways. PMID: 18479896 Ref: Tumour cell survival signalling by the ERK1/2 pathway. PMID: 18846109 Ref: MAP kinases in proliferating human colon cancer Caco-2 cells. PMID: 19301097 Ref: Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. PMID: 19331159 Ref: KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. PMID: 19372556 Ref: Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. PMID: 19396842 Ref: Tax1 enhances cancer cell proliferation via Ras-Raf-MEK-ERK signaling pathway. PMID: 19472191 Ref: Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. PMID: 19474002 Ref: Inhibition of MEK sensitizes paclitaxel-induced apoptosis of human colorectal cancer cells by downregulation of GRP78. PMID: 19521235 Ref: Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. PMID: 19569244 Ref: Carbachol induces p70S6K1 activation through an ERK-dependent but Akt-independent pathway in human colonic epithelial cells. PMID: 19615971 Ref: Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. PMID: 19637312 Ref: HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. PMID: 19638428 Ref: Up-regulation of Kruppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha. PMID: 19671674 Ref: Down-regulation of Cdx2 in colorectal carcinoma cells by the Raf-MEK-ERK 1/2 pathway. PMID: 19686845 Ref: Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. PMID: 19843849 Ref: Aurora-A overexpression enhances cell-aggregation of Ha-ras transformants through the MEK/ERK signaling pathway. PMID: 20003375 |
Ref: Role of cyclin inhibitor protein p21 in the inhibition of HCT116 human colon cancer cell proliferation by American ginseng (Panax quinquefolius) and its constituents. PMID: 19674880 Ref: CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells. PMID: 19697327 Ref: Translational up-regulation of Aurora-A in EGFR-overexpressed cancer. PMID: 19799648 Ref: Geldanamycin and its anti-cancer activities. PMID: 19850405 Ref: Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models. PMID: 20053779 Ref: Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. PMID: 20167130 Ref: High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cells. PMID: 20181064 Ref: The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells. PMID: 20348947 Ref: Induction of the apoptosis inhibitor ARC by Ras in human cancers. PMID: 20392691 Ref: Oncogenic K-ras activates p38 to maintain colorectal cancer cell proliferation during MEK inhibition. PMID: 20413844 Ref: GABA-receptor agonist, propofol inhibits invasion of colon carcinoma cells. PMID: 20888181 Ref: Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. PMID: 20923857 Ref: The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. PMID: 20942929 Ref: FMNL2 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition. PMID: 21071512 Ref: Pifithrin-alpha, an inhibitor of p53 transactivation, up-regulates COX-2 expression through an MAPK-dependent pathway. PMID: 21071999 Ref: BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. PMID: 21098728 Ref: Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer. PMID: 21161938 Ref: Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PMID: 21170361 Ref: Detection of up to 65% of Precancerous Lesions of the Human Colon and Rectum by Mutation Analysis of APC, K-Ras, B-Raf and CTNNB1. PMID: 24212608 |
Ref: DMBT1 is a novel gene induced by IL-22 in ulcerative colitis. PMID: 20824812 Ref: MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. PMID: 21118963 Ref: Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. PMID: 21148749 Ref: KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. PMID: 21163703 Ref: Activation and involvement of Ral GTPases in colorectal cancer. PMID: 21199803 Ref: Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK. PMID: 21317303 Ref: 5-Methoxyflavanone induces cell cycle arrest at the G2/M phase, apoptosis and autophagy in HCT116 human colon cancer cells. PMID: 21616090 Ref: Aspirin reduces the apoptotic effect of etoposide via Akt activation and up-regulation of p21(cip). PMID: 21617849 Ref: Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. PMID: 21705440 Ref: Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PMID: 21738740 Ref: PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PMID: 21829508 Ref: [Transcriptomic regulation and molecular mechanism of polygenic tumor at different stages]. PMID: 21873780 Ref: Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. PMID: 21923915 Ref: Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. PMID: 21985784 Ref: BRAF mutations in advanced cancers: clinical characteristics and outcomes. PMID: 22039425 Ref: Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PMID: 22174910 |
Ref: Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients. PMID: 21989899 Ref: Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? PMID: 22043994 Ref: Expression of SPRR3 is associated with tumor cell proliferation in less advanced stages of breast cancer. PMID: 22076481 Ref: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. PMID: 22147942 Ref: Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. PMID: 22169769 Ref: Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. PMID: 22173548 Ref: Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. PMID: 22180495 Ref: Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia. PMID: 22246856 Ref: Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. PMID: 22247021 Ref: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. PMID: 22261800 Ref: Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). PMID: 22271687 Ref: A new model for raf kinase inhibitory protein induced chemotherapeutic resistance. PMID: 22279539 Ref: Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation. PMID: 22298595 Ref: NF-kappaB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IkappaBalpha pathway. PMID: 22327383 Ref: Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells. PMID: 22359623 Ref: ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. PMID: 22376079 Ref: Oncogenic KRAS regulates BMP4 expression in colon cancer cell lines. PMID: 22383492 Ref: Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. PMID: 22392911 Ref: Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. PMID: 22401294 Ref: Rottlerin induces apoptosis of HT29 colon carcinoma cells through NAG-1 upregulation via an ERK and p38 MAPK-dependent and PKC delta-independent mechanism. PMID: 22410117 Ref: The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. PMID: 22415236 Ref: Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside. PMID: 22471666 Ref: Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. PMID: 22496204 Ref: Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. PMID: 22569000 Ref: MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. PMID: 22580051 Ref: KRAS mutant colorectal tumors: past and present. PMID: 22714415 Ref: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. PMID: 22722830 Ref: Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. PMID: 22723336 Ref: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. PMID: 22773810 Ref: K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. PMID: 22909976 Ref: Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells. PMID: 22922669 Ref: Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis. PMID: 23119029 Ref: MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. PMID: 23178117 Ref: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. PMID: 23259591 Ref: Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. PMID: 23317280 Ref: (18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. PMID: 23372439 Ref: [Progress of anti-tumor study based on BRAF]. PMID: 23460959 |
Ref: Diallyl sulfide, diallyl disulfide, and diallyl trisulfide inhibit migration and invasion in human colon cancer colo 205 cells through the inhibition of matrix metalloproteinase-2, -7, and -9 expressions. PMID: 21695758 Ref: Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. PMID: 22430215 Ref: Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. PMID: 22948716 Ref: CD133 affects the invasive ability of HCT116 cells by regulating TIMP-2. PMID: 23195431 Ref: Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. PMID: 23233484 Ref: BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications. PMID: 23246082 Ref: Effect of genomic instability and mutations on the signaling pathways in colon cancer cells. PMID: 23277013 Ref: MAT2B-GIT1 interplay activates MEK1/ERK 1 and 2 to induce growth in human liver and colon cancer. PMID: 23325601 Ref: Quantitative NMR analysis of Erk activity and inhibition by U0126 in a panel of patient-derived colorectal cancer cell lines. PMID: 23360766 Ref: Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways. PMID: 23363445 Ref: Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. PMID: 23365119 Ref: Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. PMID: 23438367 Ref: YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models. PMID: 23594209 Ref: Activation of ERK signaling and induction of colon cancer cell death by piperlongumine. PMID: 23603476 Ref: Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. PMID: 23629727 Ref: S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer. PMID: 23693020 Ref: Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells. PMID: 23749901 Ref: Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. PMID: 23757356 Ref: Overexpression of peptide deformylase in breast, colon, and lung cancers. PMID: 23815882 Ref: Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PMID: 23844038 Ref: Garcinia benzophenones inhibit the growth of human colon cancer cells and synergize with sulindac sulfide and turmeric. PMID: 23848206 Ref: Actein induces calcium release in human breast cancer cells. PMID: 23939423 Ref: miR-133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway. PMID: 23968734 Ref: Src plays a key role in ADAM28 expression in v-src-transformed epithelial cells and human carcinoma cells. PMID: 24007880 Ref: Metastatic SW620 colon cancer cells are primed for death when detached and can be sensitized to anoikis by the BH3-mimetic ABT-737. PMID: 24030153 Ref: Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. PMID: 24045180 Ref: Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. PMID: 24259629 Ref: Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. PMID: 24298448 Ref: Modulation of beta-catenin signaling by the inhibitors of MAP kinase, tyrosine kinase, and PI3-kinase pathways. PMID: 24324366 Ref: The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. PMID: 24330663 Ref: The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice. PMID: 24339963 |
Ref: The molecular chaperone Cosmc enhances malignant behaviors of colon cancer cells via activation of Akt and ERK. PMID: 23390052 Ref: ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. PMID: 23624914 Ref: Caffeine inhibits paclitaxelinduced apoptosis in colorectal cancer cells through the upregulation of Mcl1 levels. PMID: 24173825 Ref: The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. PMID: 24184540 Ref: The ErbB/HER family of protein-tyrosine kinases and cancer. PMID: 24269963 Ref: BRAF inhibitors in cancer therapy. PMID: 24325952 Ref: Is biomarker research advancing in the era of personalized medicine for head and neck cancer? PMID: 24442754 Ref: Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer. PMID: 24458108 Ref: ent-kaurane diterpenoids from Croton tonkinensis induce apoptosis in colorectal cancer cells through the phosphorylation of JNK mediated by reactive oxygen species and dual-specificity JNK kinase MKK4. PMID: 24476312 Ref: MKK7 mediates miR-493-dependent suppression of liver metastasis of colon cancer cells. PMID: 24533778 Ref: Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. PMID: 24553387 Ref: MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. PMID: 24561623 Ref: Desacetyluvaricin induces S phase arrest in SW480 colorectal cancer cells through superoxide overproduction. PMID: 24591255 Ref: ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a. PMID: 24684457 Ref: Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. PMID: 24685132 Ref: The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study. PMID: 24700299 Ref: Vemurafenib. PMID: 24756795 Ref: Trametinib. PMID: 24756797 Ref: Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. PMID: 24812410 Ref: Acquired resistance to EGFR-targeted therapies in colorectal cancer. PMID: 24913799 Ref: ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. PMID: 24931611 Ref: Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. PMID: 24947927 Ref: Phloroglucinol induces apoptosis through the regulation of insulin-like growth factor 1 receptor signaling pathways in human colon cancer HT-29 cells. PMID: 24970012 Ref: The study of a novel sorafenib derivative HLC-080 as an antitumor agent. PMID: 25004130 Ref: BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. PMID: 25013510 Ref: Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer. PMID: 25174975 Ref: Phospholipase Cdelta1 induces E-cadherin expression and suppresses malignancy in colorectal cancer cells. PMID: 25197077 Ref: Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines. PMID: 25309914 Ref: Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PMID: 25401499 Ref: Inhibition of TMEM16A expression suppresses growth and invasion in human colorectal cancer cells. PMID: 25541940 |
Ref: A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. PMID: 24469059 Ref: Crude extract of Rheum palmatum L inhibits migration and invasion of LS1034 human colon cancer cells acts through the inhibition of matrix metalloproteinase-2/-9 by MAPK signaling. PMID: 24497447 Ref: TNF-alpha promotes invasive growth through the MET signaling pathway. PMID: 25306394 Ref: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. PMID: 25322874 Ref: Impact of the mitogen-activated protein kinase pathway on the subproteome of detergent-resistant microdomains of colon carcinoma cells. PMID: 25359454 Ref: B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. PMID: 25381152 Ref: PKC/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects. PMID: 25430564 Ref: Spontaneously hyperactive MEK-Erk pathway mediates paradoxical facilitation of cell proliferation in mild hypoxia. PMID: 25497211 Ref: Oncogenic KRAS signalling promotes the Wnt/beta-catenin pathway through LRP6 in colorectal cancer. PMID: 25500543 Ref: Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. PMID: 25514114 Ref: Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer. PMID: 25569743 Ref: Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. PMID: 25637165 Ref: HGF-activated colonic fibroblasts mediates carcinogenesis of colonic epithelial cancer cells via PKC-cMET-ERK1/2-COX-2 signaling. PMID: 25643632 Ref: MUC1-C activates the TAK1 inflammatory pathway in colon cancer. PMID: 25659581 Ref: Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. PMID: 25673644 Ref: The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent. PMID: 25692620 Ref: PCK3145 inhibits proliferation and induces apoptosis in breast and colon cancer cells. PMID: 25750288 Ref: HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway. PMID: 25778491 Ref: Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. PMID: 25785246 Ref: Methionine adenosyltransferase 2B-GIT1 complex serves as a scaffold to regulate Ras/Raf/MEK1/2 activity in human liver and colon cancer cells. PMID: 25794709 Ref: HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL. PMID: 25813020 Ref: Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling. PMID: 25847954 Ref: Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Delta716) mice involves stromal COX-2. PMID: 25855137 Ref: A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. PMID: 25861837 Ref: Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma. PMID: 25884645 Ref: HGUE-C-1 is an atypical and novel colon carcinoma cell line. PMID: 25885658 Ref: Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. PMID: 25889309 Ref: KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. PMID: 25933688 Ref: Colorectal Carcinogenesis: Connecting K-RAS-Induced Transformation and CREB Activity In Vitro and In Vivo. PMID: 25934695 Ref: Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. PMID: 25943534 Ref: Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. PMID: 25961376 Ref: PD-L1 blockade for cancer treatment: MEDI4736. PMID: 25965366 Ref: Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells. PMID: 25973297 Ref: Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. PMID: 26028667 Ref: Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. PMID: 26058013 Ref: Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. PMID: 26136684 Ref: FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7. PMID: 26183471 Ref: The S100P/RAGE signaling pathway regulates expression of microRNA-21 in colon cancer cells. PMID: 26193421 Ref: The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. PMID: 26245900 Ref: SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. PMID: 26258891 Ref: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. PMID: 26272063 Ref: Multidrug Resistance-Associated Protein 2 Expression Is Upregulated by Adenosine 5'-Triphosphate in Colorectal Cancer Cells and Enhances Their Survival to Chemotherapeutic Drugs. PMID: 26295158 Ref: Rhomboid domain containing 1 promotes colorectal cancer growth through activation of the EGFR signalling pathway. PMID: 26300397 Ref: Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. PMID: 26351322 Ref: Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. PMID: 26392102 Ref: Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. PMID: 26392303 Ref: Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. PMID: 26404261 Ref: Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. PMID: 26427914 Ref: Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. PMID: 26439693 Ref: Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice. PMID: 26452385 Ref: Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro. PMID: 26497930 Ref: Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. PMID: 26498038 Ref: Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models. PMID: 26599335 Ref: BRAF in metastatic colorectal cancer: the future starts now. PMID: 26615988 |
Ref: PRDM1, a Tumor-Suppressor Gene, is Induced by Genkwadaphnin in Human Colon Cancer SW620 Cells. PMID: 26096175 Ref: RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. PMID: 26350096 Ref: Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6. PMID: 26369631 Ref: Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression. PMID: 26496897 Ref: Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. PMID: 26644315 Ref: A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. PMID: 26644411 Ref: A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. PMID: 26666244 Ref: HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. PMID: 26690310 Ref: Gab2 facilitates epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling in colorectal cancer. PMID: 26754532 Ref: Efficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles as AZD6244 nanocarriers in a 3D colorectal cancer in vitro model. PMID: 26786002 Ref: Exploiting the CRISPR/Cas9 PAM Constraint for Single-Nucleotide Resolution Interventions. PMID: 26788852 Ref: BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. PMID: 26802026 Ref: EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. PMID: 26810733 Ref: Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. PMID: 26820797 Ref: Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity. PMID: 26864072 Ref: GeneGazer: A Toolkit Integrating Two Pipelines for Personalized Profiling and Biosignature Identification. PMID: 26912804 Ref: AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin. PMID: 26918349 Ref: Impact of Cellular Genetic Make-up on Colorectal Cancer Cell Lines Response to Ellagic Acid: Implications of Small Interfering RNA. PMID: 26925673 Ref: Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. PMID: 26959608 Ref: Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. PMID: 26983878 Ref: BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. PMID: 27048246 Ref: The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status. PMID: 27072218 Ref: Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer. PMID: 27081080 Ref: MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers. PMID: 27082577 Ref: miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling. PMID: 27095166 Ref: Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. PMID: 27099521 Ref: BRD7: a novel tumor suppressor gene in different cancers. PMID: 27158366 Ref: Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. PMID: 27167191 Ref: Resistance to 3-HTMC-Induced Apoptosis Through Activation of PI3K/Akt, MEK/ERK, and p38/COX-2/PGE2 Pathways in Human HT-29 and HCT116 Colorectal Cancer Cells. PMID: 27192488 Ref: Down-regulation of tensin2 enhances tumorigenicity and is associated with a variety of cancers. PMID: 27203214 Ref: Blockage of Autophagy Rescues the Dual PI3K/mTOR Inhibitor BEZ235-induced Growth Inhibition of Colorectal Cancer Cells. PMID: 27294206 Ref: Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. PMID: 27312529 Ref: A combinatorial strategy for treating KRAS-mutant lung cancer. PMID: 27338794 Ref: BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells. PMID: 27351224 Ref: Involvement of the MEK/ERK pathway in EGF-induced E-cadherin down-regulation. PMID: 27369075 Ref: Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context. PMID: 27461835 Ref: Correction: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. PMID: 27480870 Ref: MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells. PMID: 27630293 Ref: gamma-Aminobutyric acid inhibits the proliferation and increases oxaliplatin sensitivity in human colon cancer cells. PMID: 27644246 Ref: Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis. PMID: 27648301 Ref: MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling. PMID: 27655129 Ref: RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis. PMID: 27661107 Ref: STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways. PMID: 27662663 Ref: 6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells. PMID: 27710830 Ref: Impaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocks. PMID: 27729552 Ref: RAS and BRAF in metastatic colorectal cancer management. PMID: 27747083 Ref: Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. PMID: 27765849 Ref: PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK. PMID: 27806324 Ref: Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. PMID: 27837257 Ref: CTGF enhances resistance to 5-FU-mediating cell apoptosis through FAK/MEK/ERK signal pathway in colorectal cancer. PMID: 27942222 Ref: Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. PMID: 28050146 |
Ref: BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. PMID: 27354468 Ref: FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. PMID: 27399335 Ref: A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. PMID: 27650277 Ref: Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer. PMID: 27670374 Ref: The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer. PMID: 27678457 Ref: Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. PMID: 27811010 Ref: FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway. PMID: 27926503 Ref: Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. PMID: 28002807 Ref: Interacting post-muscarinic receptor signaling pathways potentiate matrix metalloproteinase-1 expression and invasion of human colon cancer cells. PMID: 28008134 Ref: Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. PMID: 28073102 Ref: KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. PMID: 28215705 Ref: BRAF mutations are associated with increased iron regulatory protein-2 expression in colorectal tumorigenesis. PMID: 28281325 Ref: Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations. PMID: 28282860 Ref: In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer. PMID: 28301591 Ref: Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer. PMID: 28323034 Ref: Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1. PMID: 28366103 Ref: Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models. PMID: 28381545 Ref: ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. PMID: 28465216 Ref: The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation. PMID: 28472897 Ref: BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer. PMID: 28501528 Ref: Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy. PMID: 28507280 Ref: AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes. PMID: 28536078 Ref: MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. PMID: 28551618 Ref: Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. PMID: 28622036 Ref: Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. PMID: 28640835 Ref: Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model. PMID: 28649441 Ref: BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity. PMID: 28655712 Ref: A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. PMID: 28746882 Ref: Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma. PMID: 28759045 Ref: A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis. PMID: 28775144 Ref: Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers. PMID: 28783173 Ref: SUMOylation of IQGAP1 promotes the development of colorectal cancer. PMID: 28987385 Ref: A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. PMID: 29067643 Ref: Functional consequence of the p53 codon 72 polymorphism in colorectal cancer. PMID: 29100333 Ref: miR-422a inhibits cell proliferation in colorectal cancer by targeting AKT1 and MAPK1. PMID: 29118671 Ref: Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. PMID: 29312543 Ref: Anti-neoplastic drugs increase caveolin-1-dependent migration, invasion and metastasis of cancer cells. PMID: 29340103 Ref: EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function. PMID: 29383110 |
Ref: Long noncoding RNA CCAT1 promotes cell proliferation and metastasis in human medulloblastoma via MAPK pathway. PMID: 28777430 Ref: Oncogenic RAS-induced downregulation of ATG12 is required for survival of malignant intestinal epithelial cells. PMID: 28933585 Ref: Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway. PMID: 29065844 Ref: HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway. PMID: 29073728 Ref: Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. PMID: 29075780 Ref: MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma. PMID: 29193645 Ref: TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting beta-CATENIN and AKT Signaling in Colorectal Cancer. PMID: 29222171 Ref: Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. PMID: 29233910 Ref: beta-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models. PMID: 29282298 Ref: Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. PMID: 29295962 Ref: Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells. PMID: 29301589 Ref: BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. PMID: 29326440 Ref: Fucoidan downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. PMID: 29328495 Ref: Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF(V600E) Colorectal Cancer. PMID: 29431697 Ref: Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer. PMID: 29431699 Ref: Baicalin induces cellular senescence in human colon cancer cells via upregulation of DEPP and the activation of Ras/Raf/MEK/ERK signaling. PMID: 29440765 Ref: Results and challenges of immune checkpoint inhibitors in colorectal cancer. PMID: 29471676 Ref: Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. PMID: 29471699 Ref: Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. PMID: 29498789 Ref: Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. PMID: 29559746 Ref: TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [(18)F] fluorodeoxyglucose ((18)F-FDG PET). PMID: 29581845 Ref: Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. PMID: 29589315 Ref: Advances on the BRAF Front in Colorectal Cancer. PMID: 29610287 Ref: Emerging treatment options for BRAF-mutant colorectal cancer. PMID: 29628780 Ref: Collagen IV-conveyed signals can regulate chemokine production and promote liver metastasis. PMID: 29651051 Ref: BRAF-mutant colorectal cancer, a different breed evolving. PMID: 29708446 Ref: Oncogenic KRAS suppresses store-operated Ca(2+) entry and ICRAC through ERK pathway-dependent remodelling of STIM expression in colorectal cancer cell lines. PMID: 29748135 Ref: Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells. PMID: 29794421 Ref: SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. PMID: 29808006 Ref: AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells. PMID: 29846015 Ref: BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report. PMID: 29850361 Ref: NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway. PMID: 29857489 Ref: Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells. PMID: 29896883 Ref: Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation. PMID: 29928418 Ref: Erbin Suppresses KSR1-Mediated RAS/RAF Signaling and Tumorigenesis in Colorectal Cancer. PMID: 29980571 Ref: Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells. PMID: 29981429 Ref: Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells. PMID: 30023463 Ref: Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. PMID: 30118499 Ref: Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. PMID: 30181415 Ref: FABP7 promotes cell proliferation and survival in colon cancer through MEK/ERK signaling pathway. PMID: 30218856 Ref: [Regulator proteins of actin dynamics as possible targets of antineoplastic therapies]. PMID: 30229281 Ref: HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways. PMID: 30231922 Ref: Targeting colon cancer with the novel STAT3 inhibitor bruceantinol. PMID: 30348989 Ref: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. PMID: 30353166 |